EnVVeno Medical Corporation
NVNO
株式のランク
#40240
enVVeno Medical Corporation, based in Irvine, California, is a medical device... enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
株価
$10.71
最終同期: 2026-07-31
時価総額
$176.75K
変化（1日）
0.79%
変化（1年）
169,900.00%
国
US
取引 EnVVeno Medical Corporation (NVNO)
カテゴリー
Healthcare
EnVVeno Medical Corporation（NVNO）の配当利回りの履歴
EnVVeno Medical Corporation（銘柄コード: NVNO）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
過去5年間の平均配当利回り: 0.00%
EnVVeno Medical Corporation（NVNO）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
